First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
about
Antiangiogenic mechanisms and factors in breast cancer treatmentAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsA single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG
P2860
Q26751226-A681B783-3474-48B5-91E3-28E4A1427675Q26822432-87161F30-2247-46C7-8F06-0BE270156E61Q33647631-503103AD-D74F-46EA-B71A-51B7118CE77DQ33721539-1D948AB2-95D9-46C0-8EE6-9AC00AF08D93Q35966821-A65600D6-F58E-444B-A514-80CDB9F69ACEQ36228462-E0F2ADE9-C9F9-4AD4-AC24-94EC3C2B42A1Q37950522-0C2A577F-1043-45DC-9118-CA291DCDC124Q38046514-6DE85C78-678B-48F6-837C-1B56799C494AQ38322346-6A117B59-5E56-4AB9-BAD7-719008DEC807Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66Q51154238-6ED0CD75-BC3E-437B-8ABE-8955D629D1A2Q55493436-D41851A5-6184-4C4D-91A7-82B220D8AAED
P2860
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@en
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@nl
type
label
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@en
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@nl
prefLabel
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@en
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@nl
P2093
P2860
P1476
First-line bevacizumab in comb ...... el, single-arm Japanese study.
@en
P2093
Hiroji Iwata
Kenjiro Aogi
Masahiro Kashiwaba
Norikazu Masuda
Shigemitsu Takashima
Shinji Ohno
Shunji Kamigaki
Takashi Oda
Takayuki Ueno
Yasuhiro Fujiwara
P2860
P2888
P304
P356
10.1007/S10549-011-1685-X
P407
P577
2011-07-31T00:00:00Z